(AOF) – A medtech company, Carmat announces the effective resumption of the implantations of its Aeson artificial heart on a commercial basis. On October 25, Carmat announced that the notified body Dekra had approved all the changes made to Aeson, thus allowing the Company to resume its commercial establishments in the European Union and in other countries recognizing the Marking. THIS. In this context, a first commercial implementation of Aeson was carried out in a German hospital last week.
The company recalls that the resumption of implantations will continue to be done gradually, depending on the reconstitution of its stock of implantable prostheses.
In accordance with the principles it has consistently applied, the company does not plan to communicate individually on the state of health of implanted patients, nor on the performance of each implantation.
Carmat will continue to communicate on its progress when it reaches significant milestones and when it publishes its financial results.
AOF – LEARN MORE
An inevitable race for new blockbusters
The patent for Merck’s star product, the cancer drug Keytruda, which accounts for more than 35% of its sales, expires in 2028. Despite the loss, since 2019, of the patents for its three star products (Avastin, Herceptine, Rituxan) Roche was able to renew its portfolio by bringing new molecules to market. However, the discovery and launch of new drugs are increasingly expensive. AstraZeneca spends about $6 billion a year on R&D in a pharmaceutical industry where the life of a patent only lasts ten to fifteen years. This leads laboratories to withdraw from certain activities. Thus J&J, Pfizer, GSK and, no doubt, Novartis soon prefer to refocus on specialty drugs and abandon any ancillary activity.